ReviewBrain circulation
Immunomodulation of microglia/macrophages and neutrophils as immunotherapeutic targets in ischemic stroke: A narrative review.
Review in Brain circulation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neutrophil extracellular traps and microglia/macrophages interactions in stroke: from thromboinflammation to immunotherapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke (IS) remains a critical global issue characterized by high mortality and morbidity rates, primarily caused by neuronal death and brain dysfunction resulting from vascular occlusion. In secondary injuries following IS, inflammation plays a vital role, leading to increased neuronal damage and a poorer prognosis in the early stages. However, inflammation serves a dual purpose in stroke pathophysiology, promoting tissue repair and healing, especially in the later stages of stroke. Mechanical thrombectomy and intravenous thrombolysis are the primary therapeutic choices for IS. However, their narrow therapeutic windows and increased bleeding risks remain problematic. Recent research highlights the therapeutic potential of regulating immune cells, focusing on microglia, macrophages, and neutrophils, due to their dual roles in IS. Current preclinical and clinical studies have shown that this strategy holds promise in the prevention and management of IS. The aim of this review to assess the evolving landscape of immune modulation as therapeutic avenue in ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.